6:42 PM
 | 
May 03, 2016
 |  BC Extra  |  Company News

Alnylam tumbles on ALN-CC5 update

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) fell $7.98 (12%) to $60.81 on Tuesday after reporting that it will narrow its development program for paroxysmal nocturnal hemoglobinuria (PNH) therapy ALN-CC5 to target poor responders to Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and PNH patients who require...

Read the full 222 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >